GLP-1 medications require a valid prescription from a licensed healthcare provider. This guide does not advise on dosing or prescribing decisions. GHK-Cu is a research peptide that is not FDA-approved for human use. Any use of research peptides should be discussed with a physician. This guide provides independent, evidence-graded information to support informed conversations with your provider — not a substitute for one.
Why GLP-1 Weight Loss Affects Skin Differently
Moderate — Speed of loss and lean mass loss as predictors of skin laxity; established from bariatric literatureGLP-1 medications are producing a pattern of weight loss that dermatologists and plastic surgeons recognize from bariatric surgery: rapid, substantial fat reduction that outpaces the skin’s capacity to remodel. Skin is a dynamic tissue, but its remodeling timeline is measured in months, not weeks. When fat loss occurs faster than the skin can contract and reorganize its collagen structure, the result is visible laxity — the loose, hanging quality that communities are increasingly posting about.
Speed of weight loss is one of the strongest documented predictors of residual skin laxity after weight reduction. The bariatric surgery literature — the closest analog we have to GLP-1-speed weight loss in terms of rate and magnitude — consistently identifies rapid loss as a risk factor for loose skin beyond what patient age and starting BMI alone predict. GLP-1 medications are producing weight loss at rates that, in a meaningful proportion of users, approach the speed seen in post-surgical patients. Semaglutide in the STEP trials produced approximately 15% total body weight loss over 68 weeks. Tirzepatide in SURMOUNT-1 produced up to 22.5% body weight loss over 72 weeks in the highest-dose cohort. These are not slow lifestyle-change numbers.
The second factor is lean mass loss. GLP-1 medications suppress appetite so effectively that many users experience significant reductions in total food volume — and therefore total protein intake — without specifically tracking it. Muscle is metabolically active tissue that requires both adequate protein and a stimulus to maintain. Without resistance training and deliberate protein targeting, a meaningful fraction of weight lost on GLP-1 medications is lean mass rather than fat. This matters for skin directly: muscle volume underneath the skin provides structural support. When fat and muscle both decrease together, the skin loses support from two directions simultaneously. The combination of rapid fat loss and concurrent lean mass reduction is the mechanistic story behind why GLP-1 loose skin looks different from slow-lifestyle-change loose skin in many users.
Age compounds both factors. Skin elasticity decreases with age due to declining collagen synthesis, reduced elastin, and cumulative UV and environmental damage. A 50-year-old losing 60 lbs on semaglutide is working with skin that has meaningfully less remodeling capacity than a 30-year-old losing the same amount. This is not a reason to avoid GLP-1 therapy; it is a reason to prioritize the interventions that preserve skin quality from the beginning of treatment rather than waiting until laxity is established.
The interventions that most affect long-term skin outcomes on GLP-1 therapy are not primarily topical peptides — they are resistance training to preserve lean mass and protein targeting to prevent muscle catabolism. These are most effective when started at the beginning of treatment, not after laxity is already visible. The skin-support stack (collagen, hydration, GHK-Cu topical) plays a complementary role on top of that foundation.
What the GHK-Cu Viral Posts Actually Show
Preliminary — Real mechanistic basis; promising community data; no published RCT for loose skin application specificallyThe GHK-Cu before/after posts circulating in GLP-1 and peptide communities — the threads with 1,700+ upvotes and hundreds of comments — represent real user experiences. The improvements those specific people are showing are almost certainly genuine. That framing matters: this is not a case of fabricated results or supplement marketing. These are real people reporting real changes they observed in their own skin. The evidentiary question is not whether their results happened; it is what those results mean for other people making decisions about what to try.
What Viral Before/Afters Cannot Tell You
Selection bias in online before/after content is severe and systematic. The dynamic is straightforward: users who get dramatic, photogenic results post them. Users who get mild results, no results, or who experience side effects generally do not post. The viral posts you see are not a random sample of outcomes — they are the outcomes that are most remarkable in the distribution, deliberately selected by the people who experienced them. This does not mean the dramatic results are fake. It means you are seeing the tail of the distribution, not the middle.
A second critical limitation is the absence of controls for confounding interventions. The GHK-Cu before/after posts almost never include documentation of what else the user was doing during the period shown. Resistance training significantly affects skin appearance by building the muscle volume beneath it. Collagen supplementation has its own evidence base for skin quality. Substantial hydration changes are visible in skin. Time itself — the 12–24 month window during which skin continues retracting after weight stabilization — is a confound that makes attribution nearly impossible. When someone posts a remarkable result and attributes it to GHK-Cu, they may be right that GHK-Cu contributed. They cannot know whether the same result would have occurred with the other things they were doing and without the GHK-Cu, because there is no control condition.
A user who started GHK-Cu in month 3 of stable weight, was doing progressive resistance training, drinking 3L of water daily, taking oral collagen, and is 6 months post-peak weight loss cannot tell you whether GHK-Cu specifically drove the skin improvement they photographed. Every one of those other factors has its own evidence base for skin quality. This is not an argument against GHK-Cu — it is an argument for intellectual honesty about what community before/afters can and cannot prove.
The Biological Mechanism Is Real
GHK-Cu (glycine-histidine-lysine complexed with copper) is a naturally occurring human plasma tripeptide with well-characterized biological activity. It stimulates collagen synthesis and skin remodeling through multiple pathways: it activates TGF-beta signaling, increases expression of matrix metalloproteinases involved in collagen remodeling, and has documented effects on fibroblast activity. These are not speculative mechanisms — they are characterized in published biochemical literature. The biological plausibility for GHK-Cu improving skin quality is well-established. The gap is between established mechanism and demonstrated clinical outcome in the specific context of post-weight-loss laxity.
The bottom line on community posts: treat them as plausibility evidence, not efficacy evidence. They tell you that meaningful improvement is achievable for some users, that the compound appears tolerable at community-used concentrations, and that the biological story is consistent with observed results. They do not tell you the effect size you should expect, the probability of response, or whether GHK-Cu specifically was responsible for what was observed. Those are the questions that controlled trials answer, and those trials have not yet been done for this specific application.
GHK-Cu is a research peptide that has not been approved by the FDA for human therapeutic use. Injectable GHK-Cu in particular is regulated as a research compound. Individuals using or considering injectable peptides should consult a licensed physician before doing so. The discussion of community experiences in this guide is informational and does not constitute a recommendation to use these compounds.
Topical vs Injectable GHK-Cu: What the Evidence Actually Supports
Topical: Preliminary — Small RCTs showing measurable skin improvements Injectable: Emerging — Mechanistic plausibility; community data; no clinical trial for loose skinWhen evaluating GHK-Cu for skin laxity following GLP-1 weight loss, the evidence base for topical application is substantially stronger than for injectable use. This distinction matters when trying to make a principled decision rather than one driven purely by community enthusiasm.
Topical GHK-Cu: What the Research Shows
The topical GHK-Cu evidence consists primarily of small randomized controlled trials evaluating cosmetic dermatology outcomes. These studies have measured skin density, fine lines, skin thickness, and related markers, and they have generally found statistically significant improvements compared to vehicle controls. Importantly, these are not simply observational reports — they include randomization and comparison conditions, which places them above community anecdote in the evidence hierarchy even if they remain small in size.
Small randomized trials of topical GHK-Cu preparations (typically 2–3% concentration) have demonstrated improvements in: skin density by ultrasound measurement, reduction in fine line depth, improvements in skin thickness and laxity in treated areas. Study durations have ranged from 4 to 12 weeks. These findings establish that topically applied GHK-Cu at research-used concentrations produces measurable skin changes beyond placebo. They do not establish efficacy specifically for loose skin following major weight loss, which is a different and more severe presentation than the cosmetic dermatology cases studied.
Why Concentration and Product Selection Matter
Most commercially available GHK-Cu skincare products are formulated at concentrations below the 2–3% range used in the research that produced positive findings. There is a practical reason for this: higher concentrations may cause skin irritation in some users, and commercial products are formulated for the broadest tolerable use. When community members report using GHK-Cu serum and seeing results, what product they used, at what concentration, and applied with what protocol is almost never documented. If you are evaluating topical GHK-Cu, the concentration and formulation matter — a 0.1% product has a different evidence basis than a 2% product used in published research.
Microneedling and GHK-Cu Penetration
Skin penetration is a fundamental challenge for any topically applied active compound. The stratum corneum — the outermost skin layer — is an effective barrier. Microneedling (derma stamping) performed before topical application creates temporary microchannels in the skin that can meaningfully increase the penetration of active compounds applied immediately afterward. Several published dermatology studies have combined microneedling with active compound application and found enhanced outcomes compared to either intervention alone. For GHK-Cu specifically, this combination is used in clinical aesthetic practice and in community protocols, and the mechanistic rationale for enhanced penetration is sound. The specific evidence for microneedling plus GHK-Cu for post-weight-loss laxity is not established in controlled trials, but the mechanism-based rationale for improved delivery is clear.
Injectable GHK-Cu: The Evidence Picture
Injectable GHK-Cu occupies a different position in the evidence hierarchy than topical. There are no published clinical trials evaluating subcutaneous or intramuscular GHK-Cu injection for skin laxity following weight loss. The community using injectable GHK-Cu reports subjective improvements in skin quality, skin tone, and overall appearance — and these reports are consistent enough across independent users in different communities to be taken seriously as preliminary signal. But the absence of trial data means there is no controlled evidence base from which to establish expected effect size, optimal dosing, or comparative efficacy versus topical application.
The mechanism for injectable GHK-Cu producing skin benefits is biologically plausible: systemic delivery could, in principle, stimulate collagen synthesis at sites beyond the local application area, including deeper skin layers and areas where topical penetration is limited. GHK-Cu is found naturally in human plasma and has been measured in tissues throughout the body. Whether exogenously administered injectable GHK-Cu reaches effective concentrations in skin tissue and produces meaningful remodeling is the question that trial data would answer and that currently requires inference from mechanism and community reports.
No published clinical trials for injectable GHK-Cu as a loose skin treatment. Mechanism (systemic collagen synthesis stimulation, fibroblast activation) is biologically plausible. Community reports of skin quality improvement are consistent across multiple independent forums. Safety profile appears tolerable at community-used doses based on self-reports, but formal safety data for injectable human use is not established. For most people considering GHK-Cu for GLP-1 loose skin, topical application is the evidence-based starting point. Injectable use should involve a physician consultation.
Prescription Status and Compounding Context
GHK-Cu is not an FDA-approved drug. It exists in a regulatory gray area as a research compound. Some compounding pharmacies have formulated injectable GHK-Cu preparations, typically for use under physician supervision in aesthetic medicine and peptide therapy practices. If you are considering injectable GHK-Cu, the appropriate pathway is through a physician who understands peptide pharmacology and can provide appropriate oversight — not self-procurement from internet sources without medical guidance. The community has normalized a pattern of self-directed injectable peptide use that carries real risks in the absence of medical oversight, including injection site infections, contamination from non-pharmaceutical-grade sources, and the absence of any monitoring for adverse effects.
Resistance Training: The Most Evidence-Backed Tool for Skin Laxity on GLP-1s
Strong — Well-established evidence for muscle preservation during weight loss; directly relevant to skin laxity mechanismsIf you are using a GLP-1 medication and concerned about loose skin, resistance training is the highest-evidence intervention available to you by a significant margin. This is not nuanced or debatable in the way that GHK-Cu evidence is nuanced: the literature on resistance training, lean mass preservation during weight loss, and the relationship between muscle volume and skin appearance is well-developed and consistent across multiple study designs and populations.
The mechanism for why resistance training addresses skin laxity is direct and threefold. First, building and preserving muscle creates volume underneath the skin. The loose, draping quality of lax skin is partly a function of the tissue losing the structural support that previously held it in place. Fat loss removes that support; muscle building provides a different form of support. Users who do progressive resistance training throughout their GLP-1 weight loss period consistently report and objectively demonstrate less visible skin laxity per pound lost than users who lose weight through dietary restriction alone. This finding tracks mechanistically: they are replacing fat volume with muscle volume, changing the shape of what is underneath the skin without removing the underlying support entirely.
Second, preserving lean mass during GLP-1 use requires deliberate effort because the appetite suppression GLP-1 medications produce reduces total food intake, and with it, total protein intake. Most GLP-1 users who are not specifically targeting protein are eating significantly less protein than the 1.2–1.6 g/kg/day that exercise physiology literature identifies as the range needed to support muscle preservation during caloric restriction. Muscle is catabolized when protein intake is insufficient relative to metabolic demands — this is not a theoretical risk, it is a documented outcome in studies of GLP-1 users who do not prioritize protein. GLP-1 communities have increasingly recognized this, and the “protein first” dietary principle has become well-established in informed GLP-1 user groups as a result. It is not just weight loss optimization advice; it is skin preservation strategy.
Analyses of body composition changes in tirzepatide trials have documented that, like other GLP-1 medications, a fraction of weight lost is lean mass in addition to fat mass. The proportion varies by whether resistance training is reported. Users who prioritize protein and resistance training preserve more lean mass per pound of total weight lost. The skin implications of lean mass preservation are direct: muscle volume under skin is the structural support that determines whether loose skin appears as the fat is lost.
- Begin resistance training at the start of GLP-1 therapy, not after significant weight is already lost. The goal is lean mass preservation from the beginning of the loss period, not recovery after laxity has developed.
- Target 1.2–1.6 g/kg of bodyweight per day in protein. Use your starting or goal bodyweight to calculate the target. Most GLP-1 users eating ad libitum with suppressed appetite will be significantly below this without deliberate effort.
- Prioritize protein at every meal before other macronutrients. Given that GLP-1 appetite suppression reduces total meal volume, every bite counts more — putting protein first ensures that reduced total intake is disproportionately protein rather than disproportionately carbohydrates or fat.
- Progressive overload matters. Maintaining the same weight and rep scheme over time does not produce the muscle stimulus for hypertrophy or preservation. Aim to increase load, volume, or intensity gradually. Three to four sessions per week hitting major muscle groups is a well-established minimum for meaningful lean mass outcomes.
- Compound movements (squats, deadlifts, rows, pressing) provide the highest stimulus per unit of training time and recruit the large muscle groups that most affect body composition and skin appearance. These should form the core of a program for GLP-1 users.
- Discuss exercise capacity and any relevant medical considerations with your prescribing physician, particularly if you have cardiovascular or orthopedic conditions that affect what types of resistance training are appropriate for you.
The third mechanism by which resistance training benefits skin during GLP-1 weight loss is metabolic and systemic. Resistance training improves insulin sensitivity, which complements the GLP-1 mechanism itself. It stimulates growth hormone and IGF-1 pathways that have documented effects on skin collagen synthesis and thickness. Exercise has been associated with improved skin elasticity in multiple observational studies, though the mechanisms are not fully characterized. These systemic effects add to the direct structural benefit of muscle volume under skin, making resistance training a compound-interest investment in skin outcomes during GLP-1 weight loss.
Every dollar of time and attention you invest in resistance training and protein targeting during GLP-1 weight loss does more for your long-term skin outcome than any topical or injectable peptide. Build that foundation first. Everything else is additive on top of it.
Collagen Support During GLP-1 Weight Loss
Moderate — Multiple RCTs for skin hydration and elasticity outcomes; application to post-weight-loss laxity is extrapolatedOral collagen peptide supplementation has accumulated a moderate evidence base for improving skin hydration and elasticity markers. Multiple randomized controlled trials — the majority small and industry-funded, a limitation worth noting — have shown measurable improvements in skin elasticity by cutometer or other objective measurement, improved skin hydration, and reduction in fine line appearance. The effect sizes are generally modest but consistent across studies, which is why the evidence grade is Moderate rather than Preliminary: the findings replicate across independent trials even if each individual trial is small.
The biological rationale for collagen supplementation is straightforward. Collagen is the primary structural protein of the skin dermis, comprising approximately 70-80% of its dry weight. Dermal collagen declines with age and is further stressed during rapid weight loss. Dietary collagen peptides appear to stimulate fibroblast activity and endogenous collagen synthesis — not simply by providing raw amino acid material, but through signaling pathways that the bioactive collagen peptides themselves activate. This mechanism, characterized in in vitro and some in vivo research, distinguishes collagen supplementation from simply consuming an adequate-protein diet, though adequate total protein remains the foundation.
Optimizing Collagen Supplementation During GLP-1 Use
Vitamin C Co-Administration
Vitamin C is an essential cofactor for collagen synthesis. The hydroxylation steps that are required for collagen precursors to form stable triple-helix collagen fibers are catalyzed by vitamin C-dependent enzymes. Deficiency of vitamin C impairs collagen synthesis independent of substrate availability. During periods of rapid weight loss, when total food variety and volume are reduced, subclinical vitamin C insufficiency is more common than many users recognize. Taking collagen peptides with vitamin C — either from whole food sources or as an ascorbic acid supplement — has some research support for improving outcomes compared to collagen alone. This is a low-cost, low-risk optimization worth implementing.
Hydration and Skin Elasticity
Adequate hydration is one of the most consistently overlooked variables in skin elasticity optimization. Skin turgor and elasticity are measurably better in well-hydrated skin, and the relationship is direct: water content in the dermis affects the mechanical properties of collagen fibers and their ability to return to baseline after deformation. GLP-1 users reducing food intake are also often reducing water intake from food (fruits and vegetables have significant water content), making deliberate hydration attention more important. The common recommendation of eight glasses of water daily is not evidence-derived, but adequate total fluid intake — approximately 35 ml/kg of bodyweight for most adults — is well-supported as important for skin health.
Sun Protection During Weight Loss
UV radiation degrades both collagen and elastin in the skin dermis through direct photooxidative damage and through upregulation of matrix metalloproteinases that break down extracellular matrix proteins. The UV contribution to skin laxity compounds with age and is additive to the laxity produced by weight loss. For someone actively losing weight and trying to preserve skin quality, consistent broad-spectrum sunscreen use is not a minor or optional consideration — UV-mediated elastin degradation is accelerated during the same remodeling period when the skin is attempting to adapt to volume changes. This means sun protection is a direct complement to any collagen-preservation strategy during GLP-1 weight loss.
The collagen support stack most consistent with the evidence base: (1) 10-15g daily oral collagen peptides taken with a source of vitamin C; (2) adequate total protein intake (1.2-1.6 g/kg/day) as the foundation; (3) deliberate hydration targeting approximately 35 ml/kg/day; (4) daily broad-spectrum SPF 30+ sunscreen on exposed areas. These four interventions each have their own evidence basis and are complementary rather than redundant. None replaces resistance training as the primary structural intervention for skin laxity.
Sleep Quality and Skin Regeneration
Skin cell regeneration is accelerated during sleep, and growth hormone release during slow-wave sleep drives collagen synthesis and tissue repair. Sleep deprivation reduces skin collagen synthesis and is associated with accelerated skin aging markers in research settings. GLP-1 medications can disrupt sleep in some users through GI effects, particularly in the dose escalation period. Prioritizing sleep quality — including managing any GI symptoms that might interfere with it — has downstream implications for skin health that are often not recognized as part of a skin-optimization strategy. If GI side effects are disrupting your sleep, that is worth discussing with your prescribing physician, not merely tolerating as expected. Optimizing sleep is not just general wellness advice during GLP-1 use; it is a direct input to the skin remodeling process you are trying to support.
Managing Expectations by Amount Lost
The most useful thing an independent information source can do for someone navigating post-GLP-1 loose skin is provide honest, calibrated expectations based on what the bariatric and weight loss medicine literature actually shows. The internet tends toward two failure modes: either dismissing loose skin as a vanity concern not worth addressing, or promoting interventions as if they will resolve major hanging skin in any user who tries them. Both are disservices. The realistic picture is more differentiated than either extreme.
High likelihood of good skin retraction over 12–24 months with resistance training, collagen support, and hydration. Peptides and topicals can support quality. Most users in this range who prioritize these interventions do not end up with significant residual laxity.
Meaningful retraction expected with time and support. Peptides and collagen may improve skin quality. Some residual laxity is likely in many users, particularly if loss was rapid or resistance training was not prioritized. Realistic timeline: 18–24 months to assess final outcome.
Peptides and protocols can improve skin quality and reduce the degree of laxity. For major hanging skin, surgical intervention is likely the only definitive solution. Non-surgical interventions are worthwhile for quality improvement and to optimize pre-surgical condition if surgery is pursued.
These tiers are generalizations, not individual predictions. The variables that affect where any given person lands within a tier include: age (younger skin retracts better), baseline skin condition, speed of loss, whether resistance training was maintained throughout, genetics, and the degree to which skin-support interventions were prioritized. A 35-year-old who lost 70 lbs over 18 months while doing consistent resistance training and adequate protein will have a different outcome than a 55-year-old who lost 70 lbs in 8 months without any resistance training. Both are in the moderate tier, but their outcomes within that tier can be meaningfully different.
The Timeline Question: When to Evaluate Results
One of the most consistent errors in the community discussion of loose skin interventions is evaluating results too early. Skin continues retracting for 12–24 months after weight stabilization. Users who have been at their new weight for 3 months and are distressed about loose skin are evaluating their skin at the very beginning of the retraction window. The skin that will exist 18 months from goal weight stabilization is likely meaningfully better than the skin that exists at 3 months, even without any active intervention — simply because the remodeling process takes time.
The practical implication: do not assess the final outcome of any intervention — GHK-Cu, collagen, resistance training, anything — until weight has been stable for at least 6 months, and ideally longer. The 6-month benchmark is a minimum. Photographs taken at 3-month intervals from goal weight stabilization, under consistent lighting and conditions, provide the most honest tracking of what is actually changing versus the noise of day-to-day variation. Comparing results to day-zero photos taken at peak weight does not isolate intervention effects from natural retraction.
If you are in the 80+ lb range and considering surgical options, most plastic surgeons recommend waiting until weight has been stable for at least 12–18 months before surgical consultation for body contouring procedures. This is because skin continues retracting during that period, and operating too early can result in needing revision. If your weight is still changing — still on GLP-1 therapy and actively losing — surgical consultation is generally premature. Stabilize first, then assess.
Where GHK-Cu Fits in the Realistic Picture
For users in the 20–40 lb range with mild to moderate laxity, GHK-Cu topical is a reasonable addition to a protocol that already includes resistance training and collagen. It has biologically plausible mechanism, some RCT-level evidence for cosmetic skin outcomes, and the community experience data is consistent with real benefit in this use case. For users in the 40–80 lb range, GHK-Cu can support skin quality improvement as part of a comprehensive protocol, but it is unlikely to resolve significant hanging skin on its own. For users in the 80+ lb range, GHK-Cu and other non-surgical interventions are worthwhile for skin quality optimization but are not realistic as standalone solutions for major skin redundancy. Understanding where you are on this map determines how to weigh the effort and cost of these interventions relative to the realistic benefit available.
Frequently Asked Questions
Does GLP-1 weight loss cause more loose skin than losing weight through diet and exercise?
It can, for two reasons that often combine. GLP-1 medications suppress appetite strongly enough that many users lose weight faster than they would with lifestyle-only approaches, and speed of weight loss is one of the strongest predictors of skin laxity — skin cannot remodel as quickly as fat is lost. Additionally, GLP-1 users frequently lose lean mass alongside fat mass if they are not actively doing resistance training, because appetite suppression reduces total food volume and therefore protein intake. Muscle volume under the skin provides structural support; when both fat and muscle decrease together, the skin loses support from two directions simultaneously. The combination of speed of loss and lean mass reduction can produce more visible skin laxity than the same total weight lost gradually with active muscle preservation.
Does GHK-Cu actually tighten loose skin?
GHK-Cu has a plausible mechanism for skin improvement: it stimulates collagen synthesis, wound healing pathways, and skin remodeling through multiple characterized biochemical pathways. Topical GHK-Cu has small randomized controlled trial data showing improvements in skin density, fine lines, and skin thickness. That is the strongest evidence available for this compound in any skin application. For loose skin specifically following major weight loss, there is no published randomized controlled trial. The viral before/after posts showing dramatic results are real experiences for those specific users, but they are subject to extreme selection bias — the dramatic results get posted and shared, the mild results do not. What those users also did alongside GHK-Cu — resistance training, collagen supplementation, skin hydration, time — is almost never documented. The evidence grade for GHK-Cu as a loose skin treatment specifically is Preliminary: real biological plausibility, encouraging anecdotal community data, no definitive clinical evidence for this specific application.
Should I use topical or injectable GHK-Cu for skin laxity after GLP-1 weight loss?
Topical GHK-Cu has more published evidence than injectable for any skin application. Small RCTs have shown improvements in skin density, fine lines, and skin thickness with topical application at 2-3% concentrations — most commercial products are lower, so concentration selection matters. Microneedling (derma stamping) before application may improve penetration through the stratum corneum. Injectable GHK-Cu has no clinical trial data for loose skin specifically. Community reports suggest subjective skin quality improvements, and the mechanism — systemic collagen synthesis stimulation — is biologically plausible. However, GHK-Cu is a research peptide not FDA-approved for human use. If you are considering injectable peptides, consult a physician first. For most people exploring GHK-Cu for loose skin, topical application is the evidence-based starting point with the most direct research support.
What is the most evidence-backed thing I can do for loose skin while on a GLP-1?
Resistance training. This is not a close second — it is the highest-evidence intervention available for managing skin laxity during GLP-1-driven weight loss, by a significant margin. Building muscle while losing fat accomplishes three things simultaneously: it adds volume under the skin to provide structural support, it slows the rate of net laxity accumulation, and it preserves metabolic rate. Pair it with adequate protein intake: 1.2–1.6 g/kg of bodyweight per day. Most GLP-1 users eating with suppressed appetite eat substantially less protein than this without deliberate effort. The combination of progressive resistance training and protein targeting is the foundation. GHK-Cu, collagen supplementation, and other interventions are additive on top of that foundation — not replacements for it.
I lost 60 lbs on semaglutide. Will my loose skin retract on its own?
At 40–80 lbs lost, moderate skin retraction is expected over time with the right support — but some residual laxity is likely in most people, particularly if loss was rapid and resistance training was not prioritized during the loss phase. Two important points: first, skin continues retracting for 12–24 months after weight stabilization. Do not evaluate where you will end up based on where you are the week you hit your goal weight. Second, the interventions that support skin quality — collagen supplementation, adequate hydration, sun protection, resistance training — have better effects if continued consistently over months. If at 18–24 months of stable weight you still have significant loose skin despite consistent resistance training and collagen support, that is when a consultation with a plastic surgeon about body contouring options becomes a reasonable next step.
Does collagen supplementation help with loose skin from weight loss?
Oral collagen peptide supplementation has moderate evidence for improvements in skin hydration and elasticity — multiple randomized controlled trials showing measurable improvement in skin markers, though most studies are small and industry-funded. For loose skin after weight loss specifically, there is no definitive RCT. The biological rationale is sound: collagen is the structural protein that gives skin its tensile strength and elasticity, and dietary collagen peptides appear to stimulate fibroblast activity and collagen synthesis through signaling pathways, not merely by providing amino acid building blocks. Vitamin C is required for collagen synthesis; taking collagen with vitamin C has some research support for improving outcomes. Adequate hydration is also directly relevant to skin elasticity — consistently overlooked but measurably important. Collagen supplementation is a reasonable, low-risk addition to a protocol that includes resistance training and protein targeting; it is not a standalone solution for significant laxity.